This issue of Grand Rounds in Urology reviews the current and future use of ADT in treating advanced prostate cancer, but with cost of healthcare an ever growing factor in treatment decisions, it will also examine the potential use of older antiandrogen therapies in treating patients with advanced PCa.
Presentation
Keywords
prostate carcinoma, antiandrogens
Faculty
Medical Editor:
E. David Crawford, MD
Professor of Surgery, Urology, and Radiation Oncology Head, Urologic Oncology
E. David Crawford Endowed Chair in Urologic Oncology
University of Colorado, Denver
Aurora, Colorado
Faculty:
Gerald L. Andriole, Jr., MD
Robert Killian Royce Distinguished Professor
Professor, Surgery Chief, Division of Urologic Surgery
Director, Men’s Health Center
St. Louis, Missouri
Raoul S. Concepcion, MD
Director of Advanced Therapeutics
Urology Associates, Nashville
Nashville, Tennessee
Robert E. Donohue, MD
Professor Emeritus
University of Colorado, Denver
Aurora, Colorado
Leonard G. Gomella, MD
Bernard W. Godwin Jr. Professor of Prostate Cancer
Chairman Department of Urology
Thomas Jefferson University
Philadelphia, Pennsylvania
Daniel P. Petrylak, MD
Director of Genitourinary Oncology
Co-Director, Signal Transduction Program
Yale Cancer Center
New Haven, Connecticut
J. Clifton Vestal, MD
Urologist
USMD Prostate Cancer Center
USMD Health System
Arlington, Texas
References
References
Desai A, Stadler WM, Vogelzang NJ. Nilutamide: possible utility as a second-line hormonal agent. Urology. 2001;58(6):1016-20.
Du Plessis DJ. Castration plus nilutamide vs castration plus placebo in advanced prostate cancer. A review. Urology. 1991;37(2 Suppl):20-4.
Fisher LD, Gent M, Büller HR. Active-control trials: How would a new agent compare with placebo? A method illustrated with clopidogrel, aspirin, and placebo. American Heart Journal. 2001;141(1):26–32
Kassouf W, Tanguay S, Aprikian AG. Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails. J Urol. 2003 May;169(5):1742-4.
Maximum androgen blockade in advanced prostate cancer: An overview of 22 randomised trials with 3283 deaths in 5710 patients. The Lancet. 1995;346(8970):265–9. [No Authors Listed]
Rothmann M, Li N, Chen G, Chi GYH, Temple R, Tsou H-H. Design and analysis of non-inferiority mortality trials in oncology. Statistics in Medicine. 2002;22(2):239–64.
Schellhammer PF, Sharifi R, Block NL, et al. Nical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: Final report of a double-blind, randomized, multicenter trial. Urology. 1997;50(3):330–6.
Sun M, Choueiri TK, O-P R Hamnvik, et al. Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy: Effects of Androgen-Deprivation Therapy. JAMA Oncol. 2016;2(4):500-7.
Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal Therapy in Metastatic Hormone- Sensitive Prostate Cancer. N Engl J 2015;373:737-46.
ABOUT THE AUTHOR
Researcher-physician E. David Crawford, MD, Jack A. Vickers Director of Prostate Research and Professor of Urology at the University of California, San Diego, has devoted his career in medicine to educating the public about men's health issues and finding effective techniques and procedures to address prostate cancer, the most common malignancy affecting men in the United States.
